Momotaro-Gene Inc. raises 1.1 billion Yen venture capital for phase II studies in the US

Momotaro-Gene, an Okayama-based venture company, has developed a novel cancer therapy based on REIC, a tumor suppressor gene, which proved promising in a US-Japan phase I study during treatment of prostate cancer and malignant mesothelioma. The new capital comes from DCI partners, a Japanese biotech startup fund.

Momotaro Gene news release, March 15, 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny